PAREXEL Named Company of the Year for the Pharmaceuticals Industry with a Gold Stevie from The American Business Awards
Company also awarded Gold Stevie Award for Best Public Relations Event
BOSTON, June 2, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, has been named Company of the Year – Pharmaceuticals in the 14th Annual American Business AwardsSM. The judges awarded PAREXEL a Gold Stevie® Award and recognized the Company’s investments in innovation and expanded capabilities across the drug development continuum in 2015 as specifics for the accolade.
“All of us at PAREXEL are committed to advancing the success of the biopharmaceutical industry in our mission to prevent and cure disease. We are honored to be recognized by The American Business Awards for our accomplishments in this regard,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “This award is a tribute to the expertise of our more than 18,000 employees around the globe. They are the ones who provide innovative solutions and high-quality work to our clients every day, ensuring PAREXEL’s success.”
The American Business Awards recognized the Company for launching several new services, processes, product innovations, and academic programs in 2015. PAREXEL enhanced several critical aspects of drug development with a focus on reducing clinical trial start-up times, streamlining navigation of the global regulatory environment, enhancing regulatory submission and product registration management tools, and training the next generation biopharmaceutical workforce.
In addition to the Company of the Year – Pharmaceuticals award, PAREXEL also earned a Gold Stevie Award for Best Public Relations Event. The American Business Awards recognized the Company for increasing awareness of PAREXEL as a multinational employer of choice with significant job opportunities in Dublin.
The American Business Awards are the nation’s premier business awards program. Winners and honorees of The American Business Awards were selected from more than 3,400 entries. More than 250 professionals worldwide participated in the judging process to select this year’s Stevie Award winners.
“The judges were extremely impressed with the quality of entries we received this year. The competition was intense and every organization that has won should be proud,” said Michael Gallagher, president and founder of the Stevie Awards.
About the Stevie Awards
Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 10,000 entries each year from organizations in more than 60 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 82 locations in 51 countries around the world, and had approximately 18,450 employees in the third quarter. For more information about PAREXEL International, visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #